Diagnostic efficacy of fecal calprotectin combined with a high-sensitivity quantitative fecal immunochemical test for colorectal tumors

Table 2 Diagnostic performance of fecal calprotectin across different disease groups

Disease group	Sensitivity (95%CI)	Specificity (95%CI)	PPV (95%CI)	NPV (95%CI)	LR+	LR-	AUC (95%CI)
Adenoma	50% (33.9%-66.1%)	65% (48.5%-78.8%)	58.8% (41.4%-74.5%)	56.5% (41.6%-70.6%)	1.43 (0.85-2.41)	0.77 (0.52-1.13)	0.591 (0.466-0.716)
CRC	77.5% (61.7%-88.6%)	65% (48.5%-78.8%)	68.9% (53.5%-81.2%)	74.3% (57.1%-86.8%)	2.21 (1.41-3.49)	0.35 (0.19-0.64)	0.797 (0.697-0.897)
Presence of intestinal lesions	63.8% (52.2%-74.1%)	65% (48.5%-78.8%)	78.5% (66.8%-87.2%)	47.3% (34%-61%)	1.82 (1.16-2.87)	0.56 (0.39-0.81)	0.694 (0.6-0.787)

CRC: Colorectal cancer; CI: Confidence interval; PPV: Positive predictive value; NPV: Negative predictive value; LR+: Positive likelihood ratio; LR-: Negative likelihood ratio; AUC: Area under the receiver operating characteristic curve.